Connect with us

Health

Bat gene provides insight into fighting COVID

The study revealed that a gene common in some bats can reduce the production of the SARS-CoV-2 virus by up to 90%, which could help lead to new medical approaches to combating viral diseases. This study is part of a larger international project called Bat1K, which is attempting to sequence and assemble the genomes of […]

Published

on

Bat gene provides insight into fighting COVID


The study revealed that a gene common in some bats can reduce the production of the SARS-CoV-2 virus by up to 90%, which could help lead to new medical approaches to combating viral diseases.

This study is part of a larger international project called Bat1K, which is attempting to sequence and assemble the genomes of every living bat species, numbering around 1,500, according to Ray. It was led by the Senckenberg Research Institute and Natural History Museum in Frankfurt, Germany.

“If every individual of a species was genetically identical, they would all have the same risk associated with infection – if one dies, they all die,” Ray said. “TEs are a great way for organisms to generate genetic diversity in the species, allowing some individuals to survive better in the face of environmental pressures like viral diseases.”

Michael Hiller, professor of comparative genomics, Goethe University

“Bats have an amazing ability to resist some of the worst effects of viral infection that make us so vulnerable to certain diseases,” Ray said. “While we get very sick, the bats barely blink an eye when exposed to the same pathogens.”

The ISG15 gene from the bats, the study showed, is able to reduce production of the SARS CoV-2 virus by 80-90%. By contrast, the ISG15 gene from a human genome showed no antiviral effect in this study.

Texas Tech University

Morales, A. E., et al. (2025). Bat genomes illuminate adaptations to viral tolerance and disease resistance. Nature. doi.org/10.1038/s41586-024-08471-0.

The lab studies genomes and genome evolution with an emphasis on TEs. Their past studies have included genome research on bats and other mammals, crocodiles and various insects. The lab has worked with entities in the past such as the National Science Foundation, the U.S. Department of Agriculture, the state of Texas and the Texas Department of Wildlife and Fisheries.

Ray said his laboratory aided in the annotation of the genome assemblies in the bats. Genome annotation is how scientists characterize all component parts of the genome – the genes, regulatory sequences and non-coding and coding regions. The Texas Tech lab identified the transposable element (TE) regions of the assemblies, where bits of DNA can create new copies of themselves and introduce variations within the genome.

Michael Hiller, a professor of comparative genomics at the Goethe University and a member of the Senckenberg Institute is one of the main investigators in the study. He and Ray are both members of the executive board for the Bat1K consortium, and their relationship provided the perfect opportunity for Ray’s lab to collaborate with the international scientific community.

Ray said bats have a unique TE repertoire among mammals, presenting a potentially powerful way to generate new genetic pathways to deal with pathogens like the coronavirus.

The Ray Laboratory, led by Department of Biological Sciences Professor and Associate Chair David Ray, as part of a study on bat genomes published by the scientific journal Nature, helped identify the components of a genome in a specific species of bats that have shown more genetic adaptations in their immune systems than other animals.

Five years removed from the COVID-19 outbreak, scientists around the world are still studying its effects and, more importantly, ways those effects can be mitigated in the future. An international team of researchers may have just found a critical clue in the quest, and a laboratory at Texas Tech University played a key role.

Thus, the ISG15 gene is likely one of several factors that contribute to viral disease resistance in bats. These promising results can be used as a basis for further experimental studies, which are necessary to decipher the unique adaptations of the bats’ immune system.”
Journal reference:
Researchers in this recent study paid particular attention to the ISG15 gene, which is associated with a severe course of COVID-19 in humans. Bats are known to carry numerous viruses, including those transmissible to humans, but do not show any symptoms of disease when infected.
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health

Illinois’ first measles case of 2025 confirmed, health officials urge vaccination

CHICAGO – Illinois health officials have confirmed the state’s first measles case of the year, but they say the risk to the public remains low. What we know: The Illinois Department of Public Health (IDPH) confirmed on Wednesday that an adult in far southern Illinois tested positive for measles—the first case reported in the state […]

Published

on

Illinois' first measles case of 2025 confirmed, health officials urge vaccination

Illinois health officials have confirmed the state’s first measles case of the year, but they say the risk to the public remains low.

What we know:

The Illinois Department of Public Health (IDPH) confirmed on Wednesday that an adult in far southern Illinois tested positive for measles—the first case reported in the state this year. The diagnosis was made through laboratory testing, and at this time, it’s not considered an outbreak.

The individual received care at a local clinic, which is working with IDPH and local health officials to identify any possible exposure. Staff at the clinic were masked and considered immune, and the clinic is reviewing the immune status of any potentially exposed patients.

The general risk of community transmission remains low, but IDPH says it will keep the public informed of any new developments.

“This first reported case of measles in Illinois in 2025 is a reminder to our Illinois residents that this disease can be prevented with up-to-date vaccination,” said IDPH Director Dr. Sameer Vohra.

What we don’t know:

IDPH has not shared additional details about the affected individual, including their age and whether it’s a man or woman.

What’s next:

People who may have been exposed—and are not immune—are advised to monitor for symptoms such as rash, high fever, cough, runny nose, or red-watery eyes.

If symptoms appear, which could take up to 21 days, residents should contact a healthcare provider before visiting a clinic or hospital to prevent potential spread.

Dig deeper:

Illinois hasn’t seen any measles cases since a 2024 outbreak in Chicago that infected 67 people.

Meanwhile, outbreaks in Texas and New Mexico have totaled over 680 confirmed cases, including three deaths, two of which were children, according to reports.

IDPH is reminding residents—especially travelers and those with unvaccinated children—to check their MMR vaccine status. Two doses are 97% effective in preventing measles, according to Dr. Vohra.

The state’s new Measles Outbreak Simulator Dashboard helps parents and schools assess vaccination coverage at individual schools, part of a broader effort to prepare for potential outbreaks.

Big picture view:

Vaccination rates have declined nationally since the COVID-19 pandemic, raising concerns among public health officials about the resurgence of preventable diseases like measles.

For more information about measles, visit the IDPH or CDC’s websites.

The Source: The information in this article was provided by the Illinois Department of Public Health.

HealthIllinoisNews
Continue Reading

Health

Dengue Outbreaks

Dengue is one of the most common vector-borne viral diseases today, with ongoing outbreaks in Asia and Latin America. Its spread to North America highlights its global significance, as climate change and global warming increase the likelihood of its expansion into previously unaffected regions. With the development and availability of new vaccines, policymakers must determine […]

Published

on

Dengue Outbreaks

Dengue is one of the most common vector-borne viral diseases today, with ongoing outbreaks in Asia and Latin America. Its spread to North America highlights its global significance, as climate change and global warming increase the likelihood of its expansion into previously unaffected regions.

With the development and availability of new vaccines, policymakers must determine which are most suitable for at-risk populations. This session, presented at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2025 in Vienna, Austria, explored the geographic distribution, clinical presentation, treatment algorithms, and potential use of current dengue vaccines.

In Brazil, dengue follows a seasonal pattern, peaking during the rainy season from October to May. Most cases occur in adults aged 20-59 years, with deaths primarily affecting individuals with comorbidities or those older than 60 years. Since 2010, all four serotypes have been circulating, but dengue virus (DENV) serotypes 1 (DENV-1) and 2 (DENV-2) have been most common recently.

However, 2024 has seen an unprecedented epidemic in terms of both case numbers and duration. Changes in dominant serotypes are believed to contribute to the surge in infections and shifts in disease severity.

In this context, controlling the dengue epidemic means reducing infectivity and protecting vulnerable individuals. Since mosquito vector control is complex and no specific treatment for dengue exists, vaccines are the key preventive tool. Expanding vaccine availability and including travelers in the susceptible population are crucial steps.

The speaker’s team at this conference, from the Butantan Institute in São Paulo, Brazil, has been involved in the development of one of these vaccines. It is a tetravalent live-attenuated vaccine that covers all four dengue serotypes. The vaccine originated from the Laboratory of Infectious Diseases at the US National Institutes of Health, which licensed it to interested partners for further development. In 2018, Merck Sharp & Dohme Pharmaceuticals Ltd. and the Butantan Institute began a collaboration to advance the vaccine.

The ongoing phase 3 trial is a single-dose, placebo-controlled study that has enrolled more than 16,000 participants, who will be followed for a total of 5 years. The primary goal is to assess efficacy through polymerase chain reaction diagnosis of symptomatic dengue cases and to monitor for any potential vaccine-related adverse effects.

An interim analysis was conducted after 2 years of follow-up. Data are presented for DENV-1 and DENV-2, as these were the most prevalent during the latest epidemic, with no cases of DENV serotypes 3 or 4 detected during the study period.

  • When considering DENV-1 and DENV-2 together, without differentiating participants’ serological status, the vaccine’s efficacy was 79.6%. After adjusting for prior dengue infection, efficacy increased to 89.2% compared with 73.6% in seronegative individuals.
  • For DENV-1, without adjusting for serostatus, efficacy was 89.5%, reaching 96.8% in participants with prior dengue exposure and dropping to 85.6% in those without prior exposure.
  • For DENV-2, without adjusting for serostatus, efficacy was 69.6%, rising to 83.7% in participants with prior dengue exposure and falling to 57.9% in those without prior exposure.
  • Systemic adverse effects were common (58%), though severe reactions were rare. Their frequency increased with age. The most reported adverse effects included headache, rash, and itching across all age groups, while the most frequent local reaction was pain at the injection site.

One of the vaccine’s key advantages is that it requires only a single dose, making it ideal for outbreak situations and enabling a rapid response. Although it is pending approval by the Brazilian government, it is expected to begin administration this year. It will take at least 5 years to produce enough doses to vaccinate the entire country.

This story was translated from Univadis Spain using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

TOP PICKS FOR YOU

Continue Reading

Health

Track the spread of measles in Texas

Audio recording is automated for accessibility. Humans wrote and edited the story. See our AI policy, and give us feedback. Sign up for The Brief, The Texas Tribune’s daily newsletter that keeps readers up to speed on the most essential Texas news. The number of cases reported in Texas’ historic measles outbreak has risen to […]

Published

on

Track the spread of measles in Texas


What is measles? 

How do you prevent measles?  

Can you get sick if you’re vaccinated?

Has anyone died during this outbreak? 

Where else in Texas have there been measles cases this year? 

Do we know how measles arrived in Gaines County?

I thought we fixed measles. What happened? 

When was the last time Texas had a measles outbreak?

What do we know about Gaines County’s Mennonite community? 

Who is most vulnerable to measles?

How bad can measles symptoms get? 

What are state and local agencies doing to manage this? 


Continue Reading

Trending